CCO Treatment Updates
New Classes of Antiretrovirals: The Clinical Role of Integrase Inhibitors and Entry Inhibitors
New Classes of Antiretrovirals and How They Work |
Module 1 of 3 |
|
Program Chair: Joseph J. Eron, Jr., MD
|
|
Daniel R. Kuritzkes, MD, describes the rationale for development of and clinical data on new classes of antiretroviral agents, entry inhibitors and integrase inhibitors.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize reasons why new antiretroviral agents are needed
- Describe modes of action for entry inhibitors and integrase inhibitors
- Discuss preclinical proof of concept data for these agents
|
How, When, and Why to Use Novel Agents |
Module 2 of 3 |
|
Program Chair: Joseph J. Eron, Jr., MD
|
|
Eric S. Daar, MD, describes clinical data relating to the use of agents in new classes, including the role of these agents in treatment-experienced patients with multidrug resistance.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Define the goals of therapy for treatment-experienced patients
- Summarize the clinical scenarios that support the use of CCR5 antagonists and integrase inhibitors, based on the clinical data available for these agents
- Discuss the advantages and disadvantages related to the use of CCR5 antagonists and integrase inhibitors
|
Clinical Scenarios for the Use of Novel Agents |
Module 3 of 3 |
 
- Eric S. Daar, MD
- Daniel R. Kuritzkes, MD
|
|
|
Joseph J. Eron, Jr., MD, guides the reader through the clinical decision-making process that is integral to designing regimens for patients with multidrug-resistant virus.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize goals for treatment of antiretroviral-experienced patients
- Discuss the importance of resistance testing in construction of new regimens
- Describe criteria that the clinician might use to determine if a particular drug will be active in a patient with multidrug resistance
|
Animation
The Role of Integrase in the HIV Life Cycle
 |
|
A 3D animation exploring the role of HIV’s integrase enzyme in the viral lifecycle
This animation and others are available for use offline from the Download
Library. Click here to
visit the Library.
Format: Adobe Flash |
File size: 12.50 MB
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|